Patients with early-onset, BRAF V600E–mutated metastatic colorectal cancer should receive combination therapy as soon as ...

Esperion launched a nationwide awareness campaign for bumetanide nasal spray (Enbumyst), a short-term intranasal loop ...

The FDA approved tucatinib (Tukysa; Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of ...

Sacral neuromodulation (SNM) is still considered the gold standard neuromodulation option for refractory overactive bladder ...

The FDA approved remibrutinib (Rhapsido; Novartis) today, October 7, 2026, as the first treatment for adults with symptomatic ...

Risk assessment in mantle cell lymphoma (MCL) is evolving beyond traditional clinical scores, as genomic and dynamic ...

Bilbrey’s Tennessee Oncology colleage Johnetta Blakely, MD, MS, MMHC, who is also chief medical officer for COA, has ...

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

"We believe retatrutide is a biologic application," Eli Lilly’s CEO Dave Ricks, MBA, told analysts on the company's second-quarter earnings call in August. The outcome will shape how long retatrutide ...